| Returns | 1W : -2% , 1M : 1.5%,1Y : 27.9% |
| LT : |
Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : High |
| ST : |
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
| Peers & Returns | 1W | 1M | 1Y |
| HIKAL LTD | -2% | 1.5% | 27.9% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -1.6% | -0.6% | 27.8% |
| DR REDDYS LABORATORIES LTD | -0.1% | -2.3% | 65.7% |
| DIVIS LABORATORIES LTD | -0.9% | -4.8% | 86.8% |
| CIPLA LTD | 1.8% | 0.4% | 73.9% |
| BIOCON LTD | -15.3% | -20.6% | 33.9% |
| AUROBINDO PHARMA LTD | 8% | 9.8% | 88.7% |
| LUPIN LTD | -0.8% | 10.8% | 46.3% |
| TORRENT PHARMACEUTICALS LTD | -4.2% | -5.3% | 33.1% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
24.64
P/E Calculated based on EPS of 6.85
[ Mar2020 - Standalone Results ] 2.55
P/B Calculated based on Book Value of 66.22
[ Mar2020 - Standalone Results ] 1.43
P/S Calculated based on Revenues of 1456.87 Cr
[ TTM - Standalone Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
17% -7% 17% |
| Pledged Shares |
0 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
